北京悦康科创

Beijing Yuekang Kechuang Biotechnology is the dedicated R&D subsidiary of Yuekang Pharmaceutical Group, focusing on the development of innovative nucleic acid therapeutics. The company has established robust technology platforms for mRNA vaccines and siRNA drugs, supported by proprietary lipid nanoparticle (LNP) delivery systems. Its clinical pipeline includes candidates for hypertriglyceridemia, keloids, and COVID-19, demonstrating a commitment to addressing unmet needs in metabolic, dermatological, and infectious diseases. By integrating drug discovery, translational research, and GMP-compliant manufacturing, Yuekang Kechuang aims to lead the industrialization of genomic medicine in China. The company serves as a critical innovation engine for its parent group's transition toward a biopharmaceutical-focused business model.